N-octyl-O-sulfate chitosan-modified liposomes for delivery of docetaxel: Preparation, characterization, and pharmacokinetics

Biomedicine and Pharmacotherapy

Volumn 66, Issue 1, 2012, Pages 46-51

  Qu, Guowei ^a   Wu, Xiaoli ^a   Yin, Lifang ^a   Zhang, Can ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Chitosan derivative anchored liposome; Docetaxel; Pharmacokinetics

Indexed keywords

DOCETAXEL; DRUG CARRIER; LIPOSOME; N OCTYL O SULFATE CHITOSAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG STABILITY; MALE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CHITOSAN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FLUORESCEINS; INJECTIONS, INTRAVENOUS; LIPOSOMES; MALE; PARTICLE SIZE; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN, BOVINE; TAXOIDS;

EID: 84862825890     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.09.010     Document Type: Article

References (36)

1. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 1994, 344:1267-1272.
2. Cortes J.E., Pazdur R. Docetaxel. J Clin Oncol 1995, 13:2643-2655.
3. ®. Trends Pharmacol Sci 1992, 13:134-136.
4. Park S.B., Krishnan A.V., Lin C.S., Goldstein D., Friedlander M., Kiernan M.C. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 2008, 15:3081-3094.
5. Hennenfent K.L., Govindan R. Novel formulations of taxanes: a review. Ann Oncol 2006, 17:735-749.
6. Ten Tije A.J., Verweij J., Loos W.J., Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003, 42:665-685.
7. Lorenz W., Schmal A., Schult H., Lang S., Ohmann C., Weber D., et al. Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: analysis of various components in cremophor El and development of a compound with reduced toxicity. Agents Actions 1982, 12:64-80.
8. McLeod H.L., Kearns C.M., Kuhn J.G., Bruno R. Evaluation of the linearity of docetaxel pharmacokinetics. Cancer Chemother Pharmacol 1998, 42:155-159.
9. Nuijen B., Bouma M., Schellens J.H., Beijnen J.H. Progress in the development of alternative pharmaceutical formulations of taxanes. Invest New Drugs 2001, 19:143-153.
10. Zhai G., Wu J., Xiang G., Mao W., Yu B., Li H., et al. Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery. J Nanosci Nanotechnol 2009, 9:2155-2161.
11. Musumeci T., Ventura C.A., Giannone I., Ruozi B., Montenegro L., Pignatello R., et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm 2006, 325:172-179.
12. Gao K., Sun J., Liu K., Liu X., He Z. Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel. Drug Dev Ind Pharm 2008, 34:1227-1237.
13. Ostacolo L., Marra M., Ungaro F., Zappavigna S., Maglio G., Quaglia F., et al. In vitro anticancer activity of docetaxel-loaded micelles based on poly(ethylene oxide)-poly(epsilon-caprolactone) block copolymers: do nanocarrier properties have a role?. J Control Release 2010, 48:255-263.
14. Torchilin V. Tumor delivery of macromolecular drugs based on EPR effect. Adv Drug Deliv Rev 2010, 10.1016/j.addr.2010.03.011.
15. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2010, 10.1016/j.addr.2010.04.009.
16. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990, 268:235-237.
17. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994, 54:987-992.
18. Senior J.H. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 1987, 3:123-193.
19. Ellis A.G., Crinis N.A., Webster L.K. Inhibition of etoposide eliminated in the isolated perfused rat liver by Cremophor EL and Tween 80. Cancer Chemother Pharmacol 1996, 38:81-87.
20. Loos W.J., Baker S.D., Verweij J., et al. Influence of polysorbate 80 on unbound fractions of anticancer agents. Eur J Cancer 2002, 38(Suppl.7):S38.
21. Zhang L.F., Granick S. How to stabilize phospholipid liposomes (using nanoparticles). Nano Lett 2006, 6:694-698.
22. Henriksen I., Smistad G., Karlsen J. Interactions between liposomes and chitosan. Int J Pharm 1994, 101:227-236.
23. Muzzarelli R.A.A., Muzzarelli C. Chitosan chemistry: relevance to the biomedical sciences. Adv Polym Sci 2005, 186:151-209.
24. Zhang C., Ping Q., Zhang H., Shen J. Preparation of N-alkyl-O-sulfate chitosan derivatives and micellar solubilization of taxol. Carbohydr Polym 2003, 54:137-141.
25. Zhang C., Qu G., Sun Y., Yang T., Yao Z., Shen W., et al. Biological evaluation of N-octyl-O-sulfate chitosan as a new nano-carrier of intravenous drugs. Eur J Pharm Sci 2008, 33:415-423.
26. Zhang C., Qu G., Sun Y., Wu X., Yao Z., Guo Q., et al. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel. Biomaterials 2008, 29:1233-1241.
27. Qu G., Zhu X., Zhang C., Ping Q. Modified chitosan derivative micelle system for natural anti-tumor product gambogic acid delivery. Drug Deliv 2009, 16:363-370.
28. Han H.D., Lee A., Hwang T., Song C.K., Seong H., Hyun J., et al. Enhanced circulation time and antitumor activity of doxorubicin by comblike polymer-incorporated liposomes. J Control Release 2007, 120:161-168.
29. Szoka F., Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci U S A 1978, 75:4194-4198.
30. Gubernator J., Stasiuk M., Kozubek A. Dual effect of alkylresorcinols, natural amphiphilic compounds, upon liposomal permeability. Biochim Biophys Acta 1999, 1418(2):253-260.
31. Nishiyama N., Kataoka K. Current state, achievements, future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther 2006, 112:630-648.
32. Maeda H., Bharate G.Y., Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 2009, 71:409-419.
33. Van Bommela E.M.G., Crommelin D.J.A. Stability of doxorubicin-liposomes on storage: as an aqueous dispersion, frozen or freeze-dried. Int J Pharm 1984, 22:299-310.
34. Opanasopit P., Nishikawa M., Hashida M. Factors affecting drug and gene delivery: effects of interaction with blood components. Crit Rev Ther Drug Carrier Syst 2002, 19:191-233.
35. Opanasopit P., Yokoyama M., Watanabe M., Kawano K., Maitani Y., Okano T. Influence of serum and albumins from different species on stability of camptothecin-loaded micelles. J Control Release 2005, 104:313-321.
36. Liang G., Jia-Bi Z., Fei X., Bin N. Preparation, characterization and pharmacokinetics of N-palmitoyl chitosan anchored docetaxel liposomes. J Pharm Pharmacol 2007, 59:661-667.